Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 4
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence.
Fuentes-Villalobos F, Garrido JL, Medina MA, Zambrano N, Ross N, Bravo F, Gaete-Argel A, Oyarzún-Arrau A, Amanat F, Soto-Rifo R, Valiente-Echeverría F, Ocampo R, Esveile C, Ferreira L, Cabrera J, Torres V, Rioseco ML, Riquelme R, Barría S, Alvarez R, Pinos Y, Krammer F, Calvo M, Barria MI; COVID-19 South Chile Group. Fuentes-Villalobos F, et al. Among authors: oyarzun arrau a. Front Immunol. 2022 Feb 7;13:796481. doi: 10.3389/fimmu.2022.796481. eCollection 2022. Front Immunol. 2022. PMID: 35197972 Free PMC article.
Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile.
Beltrán-Pavez C, Riquelme-Barrios S, Oyarzún-Arrau A, Gaete-Argel A, González-Stegmaier R, Cereceda-Solis K, Aguirre A, Travisany D, Palma-Vejares R, Barriga GP, Gaggero A, Martínez-Valdebenito C, Corre NL, Ferrés M, Balcells ME, Fernandez J, Ramírez E, Villarroel F, Valiente-Echeverría F, Soto-Rifo R. Beltrán-Pavez C, et al. Among authors: oyarzun arrau a. Sci Adv. 2021 Feb 12;7(7):eabe6855. doi: 10.1126/sciadv.abe6855. Print 2021 Feb. Sci Adv. 2021. PMID: 33579701 Free PMC article. Clinical Trial.
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.
Bueno SM, Abarca K, González PA, Gálvez NMS, Soto JA, Duarte LF, Schultz BM, Pacheco GA, González LA, Vázquez Y, Ríos M, Melo-González F, Rivera-Pérez D, Iturriaga C, Urzúa M, Domínguez A, Andrade CA, Berríos-Rojas RV, Canedo-Marroquín G, Covián C, Moreno-Tapia D, Saavedra F, Vallejos OP, Donato P, Espinoza P, Fuentes D, González M, Guzmán P, Muñoz Venturelli P, Pérez CM, Potin M, Rojas Á, Fasce RA, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Oyarzún-Arrau A, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Sette A, Zeng G, Meng W, González-Aramundiz JV, Kalergis AM. Bueno SM, et al. Among authors: oyarzun arrau a. Clin Infect Dis. 2022 Aug 24;75(1):e792-e804. doi: 10.1093/cid/ciab823. Clin Infect Dis. 2022. PMID: 34537835 Free PMC article. Clinical Trial.
CBP80/20-dependent translation initiation factor (CTIF) inhibits HIV-1 Gag synthesis by targeting the function of the viral protein Rev.
García-de-Gracia F, Gaete-Argel A, Riquelme-Barrios S, Pereira-Montecinos C, Rojas-Araya B, Aguilera P, Oyarzún-Arrau A, Rojas-Fuentes C, Acevedo ML, Chnaiderman J, Valiente-Echeverría F, Toro-Ascuy D, Soto-Rifo R. García-de-Gracia F, et al. Among authors: oyarzun arrau a. RNA Biol. 2021 May;18(5):745-758. doi: 10.1080/15476286.2020.1832375. Epub 2020 Oct 25. RNA Biol. 2021. PMID: 33103564 Free PMC article.
The Analysis of Live-Attenuated Piscirickettsia salmonis Vaccine Reveals the Short-Term Upregulation of Innate and Adaptive Immune Genes in Atlantic Salmon (Salmo salar): An In Situ Open-Sea Cages Study.
Vargas D, Vallejos-Vidal E, Reyes-Cerpa S, Oyarzún-Arrau A, Acuña-Castillo C, Imarai M, Reyes-López FE, Sandino AM. Vargas D, et al. Among authors: oyarzun arrau a. Microorganisms. 2021 Mar 29;9(4):703. doi: 10.3390/microorganisms9040703. Microorganisms. 2021. PMID: 33805284 Free PMC article.
Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial.
Bueno SM, Abarca K, González PA, Gálvez NM, Soto JA, Duarte LF, Schultz BM, Pacheco GA, González LA, Vázquez Y, Ríos M, Melo-González F, Rivera-Pérez D, Iturriaga C, Urzúa M, Dominguez A, Andrade CA, Berrios RV, Canedo-Marroquín G, Covián C, Moreno-Tapia D, Saavedra F, Vallejos OP, Donato P, Espinoza P, Fuentes D, González M, Guzmán P, Muñoz-Venturelli P, Pérez CM, Potin M, Rojas A, Fasce R, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Oyarzún-Arrau A, Valiente-Echeverría F, Soto-Rifo R, Weiskopf D, Sette A, Zeng G, Meng W, González-Aramundiz JV, Kalergis AM. Bueno SM, et al. Among authors: oyarzun arrau a. medRxiv [Preprint]. 2021 Apr 1:2021.03.31.21254494. doi: 10.1101/2021.03.31.21254494. medRxiv. 2021. PMID: 35441164 Free PMC article. Updated. Preprint.